ERT

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Retrieved on: 
Monday, August 7, 2023

CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Key Points: 
  • "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer.
  • On May 5, 2023, the European Commission (EC) granted marketing authorization to Elfabrio (pegunigalsidase alfa) in the European Union.
  • On June 26, 2023, the Company was included in the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
  • Financial expenses, net were $0.8 million for the three months ended June 30, 2023, compared to financial income, net of $0.2 million for the three months ended June 30, 2022.

SummitET Appoints Adam Montella as Senior Vice President

Retrieved on: 
Friday, July 21, 2023

ST. PETERSBURG, Fla., July 21, 2023 /PRNewswire/ -- Summit Exercises and Training LLC (SummitET®), a Preparedness Solutions Company®, announced the addition of Adam Montella, MPA, MHS-V, CMP as the company's new Senior Vice President.

Key Points: 
  • ST. PETERSBURG, Fla., July 21, 2023 /PRNewswire/ -- Summit Exercises and Training LLC (SummitET®), a Preparedness Solutions Company®, announced the addition of Adam Montella, MPA, MHS-V, CMP as the company's new Senior Vice President.
  • With over three and a half decades of direct experience, Adam has worked in senior staff positions or advisory roles in local, state, and federal government, private industry, and non-government organizations.
  • In his role with SummitET, Adam will oversee both programs and operations to effectively coordinate and spearhead initiatives to align them with the company's strategic goals.
  • Furthermore, Adam is a current member of the Department of Energy's Emergency Management Issues Special Interest Group (EMI SIG).

Ivanhoe Mines Reports Record Quarterly Production of 103,786 Tonnes from Kamoa-Kakula Copper Complex for Q2 2023

Retrieved on: 
Wednesday, July 5, 2023

The 2023 annual production guidance for Kamoa-Kakula is maintained at between 390,000 to 430,000 tonnes of copper in concentrate.

Key Points: 
  • The 2023 annual production guidance for Kamoa-Kakula is maintained at between 390,000 to 430,000 tonnes of copper in concentrate.
  • Kamoa-Kakula's Phase 1 and 2 concentrator plants set a quarterly production record of 103,786 tonnes of copper in concentrate for Q2 2023 following the early completion of the debottlenecking program in the first quarter.
  • To view an enhanced version of this graphic, please visit:
    Kamoa-Kakula reports record quarterly production of 103,786 tonnes of copper during the second quarter of 2023, compared with 93,603 tonnes of copper in the first quarter.
  • Also during the quarter, a weekly production record of 9,710 tonnes of copper in concentrate was achieved in late April.

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

Retrieved on: 
Tuesday, June 27, 2023

Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid α-glucosidase (GAA).

Key Points: 
  • Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid α-glucosidase (GAA).
  • Amicus plans to immediately launch Pombiliti + Opfolda in Germany and is commencing reimbursement processes with healthcare authorities in other European countries.
  • “Late-onset Pompe disease is a rare, neuromuscular disorder that can have devastating consequences for patients and their families.
  • The European Commission approval for Pombiliti and Opfolda is the realization of the work of so many individuals and teams dedicated to the mission of improving the lives of people living with Pompe disease.

AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease

Retrieved on: 
Wednesday, June 21, 2023

“FDA clearance for AL1211 marks an important clinical milestone for AceLink,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.

Key Points: 
  • “FDA clearance for AL1211 marks an important clinical milestone for AceLink,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.
  • Phase 1 clinical trials evaluated both single ascending dosing and multiple ascending dosing.
  • AL1211 was orally administered to healthy volunteers as a single dose up to 60 mg or multiple doses of up to 30 mg once daily for 14 days.
  • Globotriasosylceramide (Gb3), the disease-causing lipid of Fabry Disease, was also significantly reduced.

ILUS Provides an Update on Its Industrial and Emergency Response Subsidiaries

Retrieved on: 
Tuesday, May 9, 2023

With the listing process of QIND underway, ILUS is now preparing its emergency response subsidiary, Emergency Response Technologies (ERT), for its own uplisting following its large acquisition currently in negotiation.

Key Points: 
  • With the listing process of QIND underway, ILUS is now preparing its emergency response subsidiary, Emergency Response Technologies (ERT), for its own uplisting following its large acquisition currently in negotiation.
  • Working closely with the Exchange Listing team, the ILUS and QIND management teams have made exceptional progress towards finalizing QIND’s NYSE American listing application.
  • These measures include but are not limited to:
    Completing the large US vehicle manufacturing acquisition which is currently in negotiation.
  • We believe that each subsidiary uplisting should bring significant value to ILUS Shareholders as ILUS remains the parent company reaping the rewards of all subsidiary growth and success.” said ILUS Managing Director, John-Paul Backwell.

ILUS Confirms New First Phase Deal for ILUS EV Technologies in Serbia

Retrieved on: 
Wednesday, April 26, 2023

Following the delay of its previously signed first phase Investment Project deal with the Serbian government, the company announced last week that it was completing a new first phase deal for ILUS EV Technologies and Replay Solutions.

Key Points: 
  • Following the delay of its previously signed first phase Investment Project deal with the Serbian government, the company announced last week that it was completing a new first phase deal for ILUS EV Technologies and Replay Solutions.
  • ILUS now confirms that it has secured the facility in Kragujevac, Serbia for ILUS EV Technologies to proceed with its Investment Project.
  • The site in Kragujevac, Serbia is available immediately with existing automotive engineers to be onboarded by ILUS EV Technologies as well as existing machinery for production of the company’s E-Raptor range of commercial electric Utility Vehicles.
  • In addition to securing the land, facilities, and manpower in Kragujevac for ILUS EV Technologies, further meetings are underway in Serbia this week for the Replay Solutions Investment Project as well as for the much larger Phase 2 government deal.

Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease

Retrieved on: 
Wednesday, April 26, 2023

PHILADELPHIA, April 26, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of miglustat, the enzyme stabilizer component of AT-GAA. A decision for miglustat from the European Commission (EC) is expected in the third quarter of 2023, after which the two-component therapy will be fully approved, and the Company will begin the country-by-country reimbursement and launch process. Miglustat will be commercialized under the brand name Opfolda. The biologic component of the two-component therapy, Pombiliti (cipaglucosidase alfa), was approved by the European Commission in March 2023.

Key Points: 
  • PHILADELPHIA, April 26, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of miglustat, the enzyme stabilizer component of AT-GAA.
  • The biologic component of the two-component therapy, Pombiliti (cipaglucosidase alfa), was approved by the European Commission in March 2023.
  • “With today’s positive CHMP opinion of Opfolda, we are now one step away from bringing this much-needed new treatment to adults living in Europe with late-onset Pompe disease.
  • “In clinical studies, Pombiliti and Opfolda has exhibited clinically meaningful and positive changes in the key manifestations of this challenging disease.

SurePeople Launches AI-powered Aris OS, Transforming How Leaders Build, Manage and Sustain High-Performing Teams

Retrieved on: 
Thursday, April 20, 2023

Aris leverages data to provide leaders and their teams with actionable insights, integrated tools and digital coaching to drive continuous alignment, development and high-performance across every stage of a team’s lifecycle.

Key Points: 
  • Aris leverages data to provide leaders and their teams with actionable insights, integrated tools and digital coaching to drive continuous alignment, development and high-performance across every stage of a team’s lifecycle.
  • Aris uniquely enables organizations to identify and address the root causes of their most critical people challenges, while developing more effective leaders and teams to reduce turnover, burnout and disengagement.
  • Aris deepens leaders' understanding of their teams with a proprietary psychometric algorithm — Prism — team survey capabilities, and 360-degree multi-rater assessments.
  • To sustain high performance, Aris powers an integrated suite of software applications and tools for leaders and team members in the flow of work.

David Herron Appointed as Calyx CEO

Retrieved on: 
Wednesday, April 19, 2023

GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, announces the appointment of David Herron as Calyx Chief Executive Officer (CEO).

Key Points: 
  • GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, announces the appointment of David Herron as Calyx Chief Executive Officer (CEO).
  • Prior to joining Calyx, Herron served as President and CEO of Bioclinica (now part of Clario).
  • Commenting on the appointment, Renaud Dehareng, Executive Chairman of Calyx said: “We are delighted to welcome David to the Calyx team.
  • Kate Briant, Senior Partner at CapVest, will remain a member of the Calyx Board, and as chair of GLO Healthcare.